Abstract:Essentials• Retinal vein occlusion (RVO), characterized by blood hyperviscosity, has an unclear pathogenesis.• We aimed to find out if hemorheological profile is altered by oxidative stress in RVO patients.• Red blood cell (RBC) oxidative stress is associated to whole blood viscosity and RBC deformability.• Reactive oxygen species alter RBC membrane rigidity, playing a key role in RVO pathogenesis.Summary. Background: Retinal vein occlusion (RVO) is characterized by vision loss resulting from hypoperfusion and… Show more
“…This review will briefly summarize what is currently known about the involvement of RBCs in hemostasis and thrombosis and its underappreciated importance. RBCs increase blood viscosity because of a rise in hematocrit, an increase in RBC aggregation or a decrease in RBC deformability (increasing flow resistance) Pro [2][3][4][5] Conversely, anemia is associated with low blood viscosity and bleeding tendency as a result of reduced platelet margination toward endothelium and enhanced NO availability Anti [2][3][4][5] RBCs undergo shear-dependent reversible aggregation mediated by plasma proteins (mainly fibrinogen and immunoglobulins) and/or local osmotic gradient Pro [14][15][16][70][71][72][73][74] RBCs with increased rigidity occlude small vessels Pro [11,12] Deformability of RBCs reduces frictional resistance to flow Anti [8,[11][12][13]] RBCs maintain biconcave shape and a high surface-to-volume ratio as a result of cytoskeleton and water/ions balance Pro or anti [5] RBCs migrate to the center of blood flow and push platelets toward the endothelium (margination) in a hematocrit-and shear-dependent manner Pro [59][60][61] Effects on platelet reactivity RBCs increase platelet adhesion and aggregation by release of ADP and thromboxane A 2 Pro [66,67] RBCs form aggregates with platelets via adhesive molecules (ICAM-4 and fibrinogen with aIIbb3)…”
Summary
New evidence has stirred up a long‐standing but undeservedly forgotten interest in the role of erythrocytes, or red blood cells (RBCs), in blood clotting and its disorders. This review summarizes the most recent research that describes the involvement of RBCs in hemostasis and thrombosis. There are both quantitative and qualitative changes in RBCs that affect bleeding and thrombosis, as well as interactions of RBCs with cellular and molecular components of the hemostatic system. The changes in RBCs that affect hemostasis and thrombosis include RBC counts or hematocrit (modulating blood rheology through viscosity) and qualitative changes, such as deformability, aggregation, expression of adhesive proteins and phosphatidylserine, release of extracellular microvesicles, and hemolysis. The pathogenic mechanisms implicated in thrombotic and hemorrhagic risk include variable adherence of RBCs to the vessel wall, which depends on the functional state of RBCs and/or endothelium, modulation of platelet reactivity and platelet margination, alterations of fibrin structure and reduced susceptibility to fibrinolysis, modulation of nitric oxide availability, and the levels of von Willebrand factor and factor VIII in blood related to the ABO blood group system. RBCs are involved in platelet‐driven contraction of clots and thrombi that results in formation of a tightly packed array of polyhedral erythrocytes, or polyhedrocytes, which comprises a nearly impermeable barrier that is important for hemostasis and wound healing. The revisited notion of the importance of RBCs is largely based on clinical and experimental associations between RBCs and thrombosis or bleeding, implying that RBCs are a prospective therapeutic target in hemostatic and thrombotic disorders.
“…This review will briefly summarize what is currently known about the involvement of RBCs in hemostasis and thrombosis and its underappreciated importance. RBCs increase blood viscosity because of a rise in hematocrit, an increase in RBC aggregation or a decrease in RBC deformability (increasing flow resistance) Pro [2][3][4][5] Conversely, anemia is associated with low blood viscosity and bleeding tendency as a result of reduced platelet margination toward endothelium and enhanced NO availability Anti [2][3][4][5] RBCs undergo shear-dependent reversible aggregation mediated by plasma proteins (mainly fibrinogen and immunoglobulins) and/or local osmotic gradient Pro [14][15][16][70][71][72][73][74] RBCs with increased rigidity occlude small vessels Pro [11,12] Deformability of RBCs reduces frictional resistance to flow Anti [8,[11][12][13]] RBCs maintain biconcave shape and a high surface-to-volume ratio as a result of cytoskeleton and water/ions balance Pro or anti [5] RBCs migrate to the center of blood flow and push platelets toward the endothelium (margination) in a hematocrit-and shear-dependent manner Pro [59][60][61] Effects on platelet reactivity RBCs increase platelet adhesion and aggregation by release of ADP and thromboxane A 2 Pro [66,67] RBCs form aggregates with platelets via adhesive molecules (ICAM-4 and fibrinogen with aIIbb3)…”
Summary
New evidence has stirred up a long‐standing but undeservedly forgotten interest in the role of erythrocytes, or red blood cells (RBCs), in blood clotting and its disorders. This review summarizes the most recent research that describes the involvement of RBCs in hemostasis and thrombosis. There are both quantitative and qualitative changes in RBCs that affect bleeding and thrombosis, as well as interactions of RBCs with cellular and molecular components of the hemostatic system. The changes in RBCs that affect hemostasis and thrombosis include RBC counts or hematocrit (modulating blood rheology through viscosity) and qualitative changes, such as deformability, aggregation, expression of adhesive proteins and phosphatidylserine, release of extracellular microvesicles, and hemolysis. The pathogenic mechanisms implicated in thrombotic and hemorrhagic risk include variable adherence of RBCs to the vessel wall, which depends on the functional state of RBCs and/or endothelium, modulation of platelet reactivity and platelet margination, alterations of fibrin structure and reduced susceptibility to fibrinolysis, modulation of nitric oxide availability, and the levels of von Willebrand factor and factor VIII in blood related to the ABO blood group system. RBCs are involved in platelet‐driven contraction of clots and thrombi that results in formation of a tightly packed array of polyhedral erythrocytes, or polyhedrocytes, which comprises a nearly impermeable barrier that is important for hemostasis and wound healing. The revisited notion of the importance of RBCs is largely based on clinical and experimental associations between RBCs and thrombosis or bleeding, implying that RBCs are a prospective therapeutic target in hemostatic and thrombotic disorders.
“…Cell viability, controlled by flow cytometry with propidium iodide staining, was found to exceed 95%. The erythrocyte ROS production was analysed as previously reported [16]. For a single analysis, the fluorescence signals of 100,000 erythrocytes were collected.…”
“…Thirty studies were conducted in specific anatomic categories of surgery. The two largest surgical categories were urologic (13) and abdominal (9). The urologic series had the highest number of positive studies for transfusion and thrombosis, with three MV-positive correlations and three UV-only positive correlations (no MV done), plus Yoo et al 48 who found a positive RBC volume correlation.…”
Patients with cancer have increased risk of thrombosis and often need red blood cell (RBC) transfusions. However, RBC transfusions may also promote thrombosis because of raised hematocrit and viscosity, storage-related RBC damage, and exposure to thrombogenic mediators from obsolescent RBCs. The authors conducted a literature survey for studies examining whether RBC transfusions were associated with increased risk of venous thromboembolism (VTE) in cancer patients. In perioperative cancer surgery patients with categorical comparisons of any versus no RBC transfusion, increased risk of VTE with RBC transfusion was found in 11 of 31 studies, 5 by univariate correlation only and 6 in multivariate analysis. All six multivariate-positive studies had intermediate overall rates of thrombosis (1.4–6.0%), and three were in urological surgery series. In the larger studies of > 2,000 patients (range: 2,219–44,656), the maximum odds ratio among the multivariate-positive studies was 1.3. Perioperative RBC transfusion volume was more strongly associated with VTE risk, with a positive association in six of seven studies. One large registry-based study of hospitalized cancer patients, not restricted to the perioperative setting, found an adjusted odds ratio of 1.60 (95% confidence interval: 1.53–1.67) for VTE risk in patients receiving RBCs compared with nontransfused patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.